Blood Products and Testing at NMCCL NOI.docx

The Defense Health Agency, Healthcare Contracting Division Southeast intends to negotiate a sole source modification under the authority of FAR 13.106-1(b)(1) to execute a bridge extension to The American National Red Cross, 431, 18th St, Washington, DC 20006-5310 for the provision of blood products and testing in support of Naval Medical Center Camp Lejeune, NC (NMCCL). The period of performance for this action is 01 April 2025 through 30 September 2025.

The American National Red Cross will provide the listed blood products, transportation of blood products, and patient specimen testing for the specific range of referral testing in accordance with the provided list and all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification is applicable. Blood products must meet the requirements set forth by the Food and Drug Administration (FDA), with proof of FDA registration to be provided upon reasonable request. All non-STAT blood requests shall be delivered within the requested timeframes and STAT requests delivered in approximately two hours of initiation of request. Laboratory testing services to include analytical processing shall be completed as defined in its laboratory manual, analysis, reporting of analytic results and interpretation.

Required Blood Products Red Blood Cells (RBCs) Leukoreduced Red Blood Cells (RBCs) Leukoreduced, Irradiated Red Blood Cell (RBC) Zika Testing Platelet Apheresis (PAS) Platelet Apheresis (PAS) Irradiated Platelet Apheresis (Standard) Platelet Apheresis (PAS) Pathogen Reduced Platelet Zika Testing Pooled Cryoprecipitated AHF Frozen Plasma AB Type Transport/Shipping

Required Laboratory Testing Cold Agglutinin screen Cold Agglutinin titer Antibody Screen each Media Elution, each AB ID/each panel and media DAT, each antisera AbID/each selected reagent cell Indirect tiger, per Ab ABO Type Rh Type Antigen type of donor RBCs per antigen Ag Screen with Pt Serum, per unit RBC Ag, other than ABO or D, each Rh Phenotyping complete Pre- Rx RBCs w/chemical/drugs/per cell Pretreatment with enzymes, per cell Separation by density gradient, retics Incubation: serum and drugs, each Dilution of serum, per aliquot Incubation with inhibitors, per aliquot Differential/Auto Ads, each ads IRL Case Tracking Code Miscellaneous Adsorptions, per ads Complex prep of pt cells for adsorption Hypotonic Wash RBC separation Thawing rare reagent cells, per cell Immediate Spin Crossmatch AGT Phase of Crossmatch Platelet ag typing (serology): IRL Platelet AB per test: IRL Platelet Associated Immunoglobulin Assay: IRL IRL Sample, Urgent, routine hours IRL Sample, Urgent, after hours fee IRL Request Weekend (4PM-7AM) IRL Request, Holiday (7AM to 7AM) Transportation Fee Red cell Antigen neg 1 Ag per unit Red cell Antigen neg 2 Ag per unit Red cell Antigen neg 3 Ag per unit Red cell Antigen neg 4 Ag per unit Red cell Antigen neg 5 Ag per unit Red cell Antigen neg 6 Ag per unit Red cell Antigen neg 7 Ag per unit Red cell Antigen neg 8 Ag per unit Red cell Antigen neg 9 Ag per unit Hemoglobin S, per test RBC Antigen neg ARDP high rare/unit Anti-CMV negative HPA-la neg/PLA-1 negative platelet HLA Antigen Selected platelet – category 1 Irradiated Import fee-red cell Unit search for red cells Concentration of Fluids Thawing rare reagent cells, per cell IgA Testing Expediated IgA testing Monocyte Monolayer Assay Special Antiglobulin Test Molecular: Isolation/Extraction Enzymatic Digestion Separation by Electrophoresis Amplification each Nucleic Acid seq Amplification Multiplex Pt nucleic acid multiplex/additional Reverse Transcription Mutation ID, sequencing Amplification signal Sep and ID by High Resolution Interpretation and Report RNA Stabilization Molecular Gene Analysis HLA: Cytotoxic Antibody Screen HLA: A&B Typing for Platelet Transfusion HLA: Antibody Identification, Class I, IgG or IgM HLA Antibody Screen HLA: HLA Stat Fee

There are no set-aside restrictions for this requirement. The intended procurement will be classified under North America Industry Classification System (NAICS) 621991 Blood and Organ Banks. This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font not smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information, or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract.

Capability statements are due by 12:00 P.M. ET, 31 March 2025. Capability statements shall be submitted by email ONLY as a Microsoft Word or Adobe PDF attachment to Felicia W. Smith: felicia.w.smith.civ@health.mil. In the subject line reference Blood Products and Testing. No phone calls will be accepted.